Ken Griffin Igm Biosciences, Inc. Put Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Put Options
7 transactions
Others Institutions Holding IGMS
# of Institutions
89Shares Held
20.5MCall Options Held
11.1KPut Options Held
5.1K-
Baker Bros. Advisors LP New York, NY4.09MShares$26.4 Million0.5% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.89MShares$25.1 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.08MShares$19.9 Million1.6% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$19.8 Million1.17% of portfolio
-
Goldman Sachs Group Inc New York, NY1.28MShares$8.25 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $187M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...